Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined drug and application thereof in preparing drugs for treating high-level cerebroma with postoperative recurrence and no response to standard treatment

A high-level, drug-based technology, applied in drug delivery, drug combination, medical preparations containing active ingredients, etc., can solve the problem of no chemotherapy program and achieve the effect of prolonging survival

Active Publication Date: 2019-04-05
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Currently, there is no effective chemotherapy regimen for high-grade brain tumors that relapse after surgery and fail standard treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined drug and application thereof in preparing drugs for treating high-level cerebroma with postoperative recurrence and no response to standard treatment
  • Combined drug and application thereof in preparing drugs for treating high-level cerebroma with postoperative recurrence and no response to standard treatment
  • Combined drug and application thereof in preparing drugs for treating high-level cerebroma with postoperative recurrence and no response to standard treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Combination drugs of the present invention

[0031] 1Chlorogenic acid injection

[0032] Weigh 350g of chlorogenic acid aseptically, add 850g of mannitol, and dispense into injections after preparation.

[0033] 2 Temozolomide capsules

[0034] Weigh 100 g of temozolomide aseptically, and pack them into capsules aseptically.

[0035] 3 how to use

[0036] First orally use temozolomide, and then continue to use chlorogenic acid injection according to the mass ratio of 300 (chlorogenic acid): 150 (temozolomide).

Embodiment 2

[0037] Example 2 Combination drugs of the present invention

[0038] 1 Chlorogenic acid oral tablet

[0039] Weigh 350g of chlorogenic acid aseptically, add 850g of mannitol and 250g of microcrystalline cellulose, and make oral tablets after compression.

[0040] 2 Temozolomide capsules

[0041] Weigh 100 g of temozolomide aseptically, and pack them into capsules aseptically.

[0042] 3 how to use

[0043] First orally use temozolomide, and then continue to use chlorogenic acid tablets according to the mass ratio of 300 (chlorogenic acid): 150 (temozolomide).

Embodiment 3

[0044] Example 3 Combination drugs of the present invention

[0045] 1Chlorogenic acid injection

[0046] Weigh 100g of chlorogenic acid aseptically, add 650g of mannitol, and dispense into injections after preparation.

[0047] 2 Temozolomide capsules

[0048] Weigh 100 g of temozolomide aseptically, and pack them into capsules aseptically.

[0049] 3 how to use

[0050] According to the mass ratio of 100 (chlorogenic acid): 100 (temozolomide), both temozolomide capsules and chlorogenic acid injection were used.

[0051] 4 Animal model: Temozolomide resistance animal model

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a combined drug for treating high-level cerebroma with postoperative recurrence and no response to standard treatment. The combined drug contains chlorogenic acid and temozolomide in same or different dosages and used for simultaneously or singly dosing, and a pharmacologically acceptable carrier. The invention also provides a drug compound containing chlorogenic acid and temozolomide. The invention also provides an application of the combined drug and the drug compound in preparing the drugs for treating high-level cerebroma with postoperative recurrence and no responseto standard treatment. The drug compound or combined drug provided by the invention can be used for effectively treating high-level cerebroma with postoperative recurrence and no response to standardtreatment, is capable of effectively controlling, reducing and eliminating focus of high-level cerebroma with postoperative recurrence and no response to standard treatment, and is capable of obviously prolonging lifetime of patients suffering from high-level cerebroma with postoperative recurrence and no response to standard treatment.

Description

Technical field [0001] The invention specifically relates to the use of a combined medicine and a pharmaceutical composition in the preparation of a medicine for treating high-grade brain tumors that are ineffective in standard treatment for postoperative recurrence. Background technique [0002] Brain tumors, also known as intracranial tumors and brain tumors, refer to neurological tumors that occur in the cranial cavity, including tumors originating from neuroepithelium, peripheral nerves, meninges and germ cells, tumors of lymphoid and hematopoietic tissues, and tumors of the sella Craniopharyngioma and granular cell tumor. According to the "World Health Organization Central Nervous System (CNS) Tumor Classification (2016)", which integrates tissue phenotype and gene phenotype CNS tumor classification principles, brain tumors include diffuse astrocytes and oligodendrocyte tumors, Other astrocytic tumors, ependymal tumors, choroid plexus tumors, neurons and mixed neuron-glial ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4188A61K31/216A61P35/00A61P25/00
CPCA61P25/00A61P35/00A61K31/216A61K31/4188A61K2300/00A61K9/0019A61K9/0053
Inventor 张洁陈晓光李文斌杨华蓉
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com